Nicolas Sluis-Cremer - Publications

Affiliations: 
University of Pittsburgh, Pittsburgh, PA, United States 
Area:
Virology Biology, Biochemistry

73 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Sluis-Cremer N. Therapeutic Approaches to Eradicate Latent HIV-1 in Resting CD4+ T Cells. Current Topics in Medicinal Chemistry. 16: 1191-7. PMID 26324046  0.96
2015 Venkatachari NJ, Zerbato JM, Jain S, Mancini AE, Chattopadhyay A, Sluis-Cremer N, Bar-Joseph Z, Ayyavoo V. Temporal transcriptional response to latency reversing agents identifies specific factors regulating HIV-1 viral transcriptional switch. Retrovirology. 12: 85. PMID 26438393 DOI: 10.1186/s12977-015-0211-3  0.96
2015 La J, Latham CF, Tinetti RN, Johnson A, Tyssen D, Huber KD, Sluis-Cremer N, Simpson JS, Headey SJ, Chalmers DK, Tachedjian G. Identification of mechanistically distinct inhibitors of HIV-1 reverse transcriptase through fragment screening. Proceedings of the National Academy of Sciences of the United States of America. 112: 6979-84. PMID 26038551 DOI: 10.1073/pnas.1423900112  0.96
2014 Sluis-Cremer N. The emerging profile of cross-resistance among the nonnucleoside HIV-1 reverse transcriptase inhibitors. Viruses. 6: 2960-73. PMID 25089538 DOI: 10.3390/v6082960  0.96
2014 Sheen CW, Alptürk O, Sluis-Cremer N. Novel high-throughput screen identifies an HIV-1 reverse transcriptase inhibitor with a unique mechanism of action. The Biochemical Journal. 462: 425-32. PMID 24969820 DOI: 10.1042/BJ20140365  0.96
2014 Sluis-Cremer N, Jordan MR, Huber K, Wallis CL, Bertagnolio S, Mellors JW, Parkin NT, Harrigan PR. E138A in HIV-1 reverse transcriptase is more common in subtype C than B: implications for rilpivirine use in resource-limited settings. Antiviral Research. 107: 31-4. PMID 24746459 DOI: 10.1016/j.antiviral.2014.04.001  0.96
2014 Doyon G, Sobolewski MD, Huber K, McMahon D, Mellors JW, Sluis-Cremer N. Discovery of a small molecule agonist of phosphatidylinositol 3-kinase p110α that reactivates latent HIV-1. Plos One. 9: e84964. PMID 24489654 DOI: 10.1371/journal.pone.0084964  0.96
2014 Sluis-Cremer N, Huber KD, Brumme CJ, Harrigan PR. Competitive fitness assays indicate that the E138A substitution in HIV-1 reverse transcriptase decreases in vitro susceptibility to emtricitabine. Antimicrobial Agents and Chemotherapy. 58: 2430-3. PMID 24419343 DOI: 10.1128/AAC.02114-13  0.96
2014 Rothstein SN, Huber KD, Sluis-Cremer N, Little SR. In vitro characterization of a sustained-release formulation for enfuvirtide. Antimicrobial Agents and Chemotherapy. 58: 1797-9. PMID 24366751 DOI: 10.1128/AAC.02440-13  0.96
2014 Meteer JD, Schinazi RF, Mellors JW, Sluis-Cremer N. Molecular mechanism of HIV-1 resistance to 3'-azido-2',3'-dideoxyguanosine. Antiviral Research. 101: 62-7. PMID 24211331 DOI: 10.1016/j.antiviral.2013.10.017  0.96
2013 Herman BD, Sluis-Cremer N. Transient kinetic analyses of the ribonuclease H cleavage activity of HIV-1 reverse transcriptase in complex with efavirenz and/or a β-thujaplicinol analogue. The Biochemical Journal. 455: 179-84. PMID 23927736 DOI: 10.1042/BJ20130850  0.96
2013 Xu H, Franks T, Gibson G, Huber K, Rahm N, De Castillia CS, Luban J, Aiken C, Watkins S, Sluis-Cremer N, Ambrose Z. Evidence for biphasic uncoating during HIV-1 infection from a novel imaging assay. Retrovirology. 10: 70. PMID 23835323 DOI: 10.1186/1742-4690-10-70  0.96
2013 Brumme CJ, Huber KD, Dong W, Poon AF, Harrigan PR, Sluis-Cremer N. Replication fitness of multiple nonnucleoside reverse transcriptase-resistant HIV-1 variants in the presence of etravirine measured by 454 deep sequencing. Journal of Virology. 87: 8805-7. PMID 23720723 DOI: 10.1128/JVI.00335-13  0.96
2013 Doyon G, Zerbato J, Mellors JW, Sluis-Cremer N. Disulfiram reactivates latent HIV-1 expression through depletion of the phosphatase and tensin homolog. Aids (London, England). 27: F7-F11. PMID 22739395 DOI: 10.1097/QAD.0b013e3283570620  0.96
2013 Tachedjian G, Sluis-Cremer N. Role of RNase H activity in NRTI/NNRTI drug resistance Human Immunodeficiency Virus Reverse Transcriptase: a Bench-to-Bedside Success. 281-303. DOI: 10.1007/978-1-4614-7291-9_13  0.96
2012 Yap SH, Herman BD, Radzio J, Sluis-Cremer N, Tachedjian G. N348I in HIV-1 reverse transcriptase counteracts the synergy between zidovudine and nevirapine. Journal of Acquired Immune Deficiency Syndromes (1999). 61: 153-7. PMID 22743599 DOI: 10.1097/QAI.0b013e3182657990  0.96
2012 Brehm JH, Koontz DL, Wallis CL, Shutt KA, Sanne I, Wood R, McIntyre JA, Stevens WS, Sluis-Cremer N, Mellors JW. Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 55: 737-45. PMID 22618567 DOI: 10.1093/cid/cis501  0.96
2012 McCormick KD, Liu S, Jacobs JL, Marques ET, Sluis-Cremer N, Wang T. Development of a robust cytopathic effect-based high-throughput screening assay to identify novel inhibitors of dengue virus. Antimicrobial Agents and Chemotherapy. 56: 3399-401. PMID 22391547 DOI: 10.1128/AAC.06425-11  0.96
2012 Brehm JH, Scott Y, Koontz DL, Perry S, Hammer S, Katzenstein D, Mellors JW, Sluis-Cremer N. Zidovudine (AZT) monotherapy selects for the A360V mutation in the connection domain of HIV-1 reverse transcriptase. Plos One. 7: e31558. PMID 22363673 DOI: 10.1371/journal.pone.0031558  0.96
2012 Herman BD, Schinazi RF, Zhang HW, Nettles JH, Stanton R, Detorio M, Obikhod A, Pradère U, Coats SJ, Mellors JW, Sluis-Cremer N. Substrate mimicry: HIV-1 reverse transcriptase recognizes 6-modified-3'-azido-2',3'-dideoxyguanosine-5'-triphosphates as adenosine analogs. Nucleic Acids Research. 40: 381-90. PMID 21914723 DOI: 10.1093/nar/gkr756  0.96
2011 Radzio J, Sluis-Cremer N. Subunit-specific mutational analysis of residue N348 in HIV-1 reverse transcriptase. Retrovirology. 8: 69. PMID 21859446 DOI: 10.1186/1742-4690-8-69  0.96
2011 Zhang HW, Detorio M, Herman BD, Solomon S, Bassit L, Nettles JH, Obikhod A, Tao SJ, Mellors JW, Sluis-Cremer N, Coats SJ, Schinazi RF. Synthesis, antiviral activity, cytotoxicity and cellular pharmacology of l-3'-azido-2',3'-dideoxypurine nucleosides. European Journal of Medicinal Chemistry. 46: 3832-44. PMID 21700368 DOI: 10.1016/j.ejmech.2011.05.051  0.96
2011 Meteer JD, Koontz D, Asif G, Zhang HW, Detorio M, Solomon S, Coats SJ, Sluis-Cremer N, Schinazi RF, Mellors JW. The base component of 3'-azido-2',3'-dideoxynucleosides influences resistance mutations selected in HIV-1 reverse transcriptase. Antimicrobial Agents and Chemotherapy. 55: 3758-64. PMID 21646480 DOI: 10.1128/AAC.00414-11  0.96
2011 Roy V, Obikhod A, Zhang HW, Coats SJ, Herman BD, Sluis-Cremer N, Agrofoglio LA, Schinazi RF. Synthesis and anti-HIV evaluation of 3'-triazolo nucleosides. Nucleosides, Nucleotides & Nucleic Acids. 30: 264-70. PMID 21623540 DOI: 10.1080/15257770.2011.580291  0.96
2011 Huber K, Doyon G, Plaks J, Fyne E, Mellors JW, Sluis-Cremer N. Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells. The Journal of Biological Chemistry. 286: 22211-8. PMID 21531716 DOI: 10.1074/jbc.M110.180224  0.96
2011 Brehm JH, Lalama CM, Hughes MD, Haubrich R, Riddler SA, Sluis-Cremer N, Mellors JW. Failure of initial therapy with two nucleosides and efavirenz is not associated with early emergence of mutations in the C-terminus of HIV-1 reverse transcriptase. Journal of Acquired Immune Deficiency Syndromes (1999). 56: 344-8. PMID 21350368 DOI: 10.1097/QAI.0b013e31820cf029  0.96
2010 Ganguly S, Murugesan S, Prasanthi N, Alptürk O, Herman B, Sluis-Cremer N. Synthesis and Anti-HIV-1 Activity of a Novel Series of Aminoimidazole Analogs. Letters in Drug Design & Discovery. 7: 318-323. PMID 20535242 DOI: 10.2174/157018010791163424  0.96
2010 Ahn J, Byeon IJL, Dharmasena S, Huber K, Concel J, Gronenborn AM, Sluis-Cremer N. The RNA binding protein HuR does not interact directly with HIV-1 reverse transcriptase and does not affect reverse transcription in vitro Retrovirology. 7. PMID 20459669 DOI: 10.1186/1742-4690-7-40  0.96
2010 Herman BD, Votruba I, Holy A, Sluis-Cremer N, Balzarini J. The acyclic 2,4-diaminopyrimidine nucleoside phosphonate acts as a purine mimetic in HIV-1 reverse transcriptase DNA polymerization. The Journal of Biological Chemistry. 285: 12101-8. PMID 20164190 DOI: 10.1074/jbc.M109.096529  0.96
2010 Radzio J, Yap SH, Tachedjian G, Sluis-Cremer N. N348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutations. Aids (London, England). 24: 659-67. PMID 20160634 DOI: 10.1097/QAD.0b013e328336781d  0.96
2010 Sluis-Cremer N, Moore K, Radzio J, Sonza S, Tachedjian G. N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations. Aids (London, England). 24: 317-9. PMID 20010074 DOI: 10.1097/QAD.0b013e3283315697  0.96
2010 Zhang HW, Coats SJ, Bondada L, Amblard F, Detorio M, Asif G, Fromentin E, Solomon S, Obikhod A, Whitaker T, Sluis-Cremer N, Mellors JW, Schinazi RF. Synthesis and evaluation of 3'-azido-2',3'-dideoxypurine nucleosides as inhibitors of human immunodeficiency virus. Bioorganic & Medicinal Chemistry Letters. 20: 60-4. PMID 19948402 DOI: 10.1016/j.bmcl.2009.11.031  0.96
2009 van Rooijen LB, Greengrass V, Morris LM, Plate MM, Gouillou M, Tachedjian G, Sluis-Cremer N, Hearps AC, Crowe SM. Effect of reverse transcriptase inhibitors and mutations on the low-cost Cavidi reverse transcriptase viral load assay. Journal of Acquired Immune Deficiency Syndromes (1999). 52: 527-9. PMID 19901621 DOI: 10.1097/QAI.0b013e3181b9e726  0.96
2009 Sluis-Cremer N, Koontz D, Bassit L, Hernandez-Santiago BI, Detorio M, Rapp KL, Amblard F, Bondada L, Grier J, Coats SJ, Schinazi RF, Mellors JW. Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides. Antimicrobial Agents and Chemotherapy. 53: 3715-9. PMID 19596885 DOI: 10.1128/AAC.00392-09  0.96
2009 Ambrose Z, Herman BD, Sheen CW, Zelina S, Moore KL, Tachedjian G, Nissley DV, Sluis-Cremer N. The human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor resistance mutation I132M confers hypersensitivity to nucleoside analogs. Journal of Virology. 83: 3826-33. PMID 19193782 DOI: 10.1128/JVI.01968-08  0.96
2008 Brehm JH, Mellors JW, Sluis-Cremer N. Mechanism by which a glutamine to leucine substitution at residue 509 in the ribonuclease H domain of HIV-1 reverse transcriptase confers zidovudine resistance. Biochemistry. 47: 14020-7. PMID 19067547 DOI: 10.1021/bi8014778  0.96
2008 Harrigan PR, Sheen CW, Gill VS, Wynhoven B, Hudson E, Lima VD, Lecocq P, Aguirre R, Poon AF, Sluis-Cremer N. Silent mutations are selected in HIV-1 reverse transcriptase and affect enzymatic efficiency. Aids (London, England). 22: 2501-8. PMID 19005273 DOI: 10.1097/QAD.0b013e328318f16c  0.96
2008 Bonache MC, Quesada E, Sheen CW, Balzarini J, Sluis-Cremer N, Pérez-Pérez MJ, Camarasa MJ, San-Félix A. Novel N-3 substituted TSAO-T derivatives: synthesis and anti-HIV-evaluation. Nucleosides, Nucleotides & Nucleic Acids. 27: 351-67. PMID 18404570 DOI: 10.1080/15257770801943990  0.96
2008 Sluis-Cremer N, Tachedjian G. Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors. Virus Research. 134: 147-56. PMID 18372072 DOI: 10.1016/j.virusres.2008.01.002  0.96
2008 Figueiredo A, Zelina S, Sluis-Cremer N, Tachedjian G. Impact of residues in the nonnucleoside reverse transcriptase inhibitor binding pocket on HIV-1 reverse transcriptase heterodimer stability. Current Hiv Research. 6: 130-7. PMID 18336260 DOI: 10.2174/157016208783885065  0.96
2008 Radzio J, Sluis-Cremer N. Efavirenz accelerates HIV-1 reverse transcriptase ribonuclease H cleavage, leading to diminished zidovudine excision. Molecular Pharmacology. 73: 601-6. PMID 18024510 DOI: 10.1124/mol.107.038596  0.96
2008 Zelina S, Sheen CW, Radzio J, Mellors JW, Sluis-Cremer N. Mechanisms by which the G333D mutation in human immunodeficiency virus type 1 Reverse transcriptase facilitates dual resistance to zidovudine and lamivudine. Antimicrobial Agents and Chemotherapy. 52: 157-63. PMID 17967907 DOI: 10.1128/AAC.00904-07  0.96
2007 Yap SH, Sheen CW, Fahey J, Zanin M, Tyssen D, Lima VD, Wynhoven B, Kuiper M, Sluis-Cremer N, Harrigan PR, Tachedjian G. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. Plos Medicine. 4: e335. PMID 18052601 DOI: 10.1371/journal.pmed.0040335  0.96
2007 Xia Q, Radzio J, Anderson KS, Sluis-Cremer N. Probing nonnucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by transient kinetic analyses. Protein Science : a Publication of the Protein Society. 16: 1728-37. PMID 17656585 DOI: 10.1110/ps.072829007  0.96
2007 Parikh UM, Zelina S, Sluis-Cremer N, Mellors JW. Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase. Aids (London, England). 21: 1405-14. PMID 17589186 DOI: 10.1097/QAD.0b013e3281ac229b  0.96
2007 Brehm JH, Koontz D, Meteer JD, Pathak V, Sluis-Cremer N, Mellors JW. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine. Journal of Virology. 81: 7852-9. PMID 17507476 DOI: 10.1128/JVI.02203-06  0.96
2007 Nissley DV, Radzio J, Ambrose Z, Sheen CW, Hamamouch N, Moore KL, Tachedjian G, Sluis-Cremer N. Characterization of novel non-nucleoside reverse transcriptase (RT) inhibitor resistance mutations at residues 132 and 135 in the 51 kDa subunit of HIV-1 RT. The Biochemical Journal. 404: 151-7. PMID 17286555 DOI: 10.1042/BJ20061814  0.96
2007 Sluis-Cremer N, Sheen CW, Zelina S, Torres PS, Parikh UM, Mellors JW. Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors. Antimicrobial Agents and Chemotherapy. 51: 48-53. PMID 17088490 DOI: 10.1128/AAC.00683-06  0.96
2006 Figueiredo A, Moore KL, Mak J, Sluis-Cremer N, de Bethune MP, Tachedjian G. Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol. Plos Pathogens. 2: e119. PMID 17096588 DOI: 10.1371/journal.ppat.0020119  0.96
2006 Sluis-Cremer N, Hamamouch N, San Félix A, Velazquez S, Balzarini J, Camarasa MJ. Structure-activity relationships of [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]- 3'-spiro-5' '-(4' '-amino-1' ',2' '-oxathiole-2' ',2' '-dioxide)thymine derivatives as inhibitors of HIV-1 reverse transcriptase dimerization. Journal of Medicinal Chemistry. 49: 4834-41. PMID 16884295 DOI: 10.1021/jm0604575  0.96
2006 Srivastava S, Sluis-Cremer N, Tachedjian G. Dimerization of human immunodeficiency virus type 1 reverse transcriptase as an antiviral target Current Pharmaceutical Design. 12: 1879-1894. PMID 16724954 DOI: 10.2174/138161206776873590  0.96
2006 Sluis-Cremer N, Kempner ES. Radiation target analyses of DNA template/primer complexes. Biophysical Journal. 90: L61-3. PMID 16533846 DOI: 10.1529/biophysj.106.083261  0.96
2005 Sluis-Cremer N, Arion D, Parikh U, Koontz D, Schinazi RF, Mellors JW, Parniak MA. The 3'-azido group is not the primary determinant of 3'-azido-3'-deoxythymidine (AZT) responsible for the excision phenotype of AZT-resistant HIV-1. The Journal of Biological Chemistry. 280: 29047-52. PMID 15970587 DOI: 10.1074/jbc.M503166200  0.96
2005 Radzio J, Sluis-Cremer N. Stereo-selectivity of HIV-1 reverse transcriptase toward isomers of thymidine-5'-O-1-thiotriphosphate. Protein Science : a Publication of the Protein Society. 14: 1929-33. PMID 15937285 DOI: 10.1110/ps.051445605  0.96
2005 Tachedjian G, Radzio J, Sluis-Cremer N. Relationship between enzyme activity and dimeric structure of recombinant HTV-1 reverse transcriptase Proteins: Structure, Function and Genetics. 60: 5-13. PMID 15852304 DOI: 10.1002/prot.20480  0.96
2005 Tachedjian G, Moore KL, Goff SP, Sluis-Cremer N. Efavirenz enhances the proteolytic processing of an HIV-1 pol polyprotein precursor and reverse transcriptase homodimer formation. Febs Letters. 579: 379-84. PMID 15642347 DOI: 10.1016/j.febslet.2004.11.099  0.96
2004 Sluis-Cremer N, Temiz NA, Bahar I. Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding. Current Hiv Research. 2: 323-32. PMID 15544453 DOI: 10.2174/1570162043351093  0.96
2004 Sluis-Cremer N, Arion D, Abram ME, Parniak MA. Proteolytic processing of an HIV-1 pol polyprotein precursor: insights into the mechanism of reverse transcriptase p66/p51 heterodimer formation. The International Journal of Biochemistry & Cell Biology. 36: 1836-47. PMID 15183348 DOI: 10.1016/j.biocel.2004.02.020  0.96
2003 Sluis-Cremer N, Kempner E, Parniak MA. Structure-activity relationships in HIV-1 reverse transcriptase revealed by radiation target analysis. Protein Science : a Publication of the Protein Society. 12: 2081-6. PMID 12931006 DOI: 10.1110/ps.03130503  0.96
2002 Sluis-Cremer N, Tachedjian G. Modulation of the oligomeric structures of HIV-1 retroviral enzymes by synthetic peptides and small molecules. European Journal of Biochemistry / Febs. 269: 5103-11. PMID 12392542 DOI: 10.1046/j.1432-1033.2002.03216.x  0.96
2002 Sluis-Cremer N, Arion D, Parniak MA. Destabilization of the HIV-1 reverse transcriptase dimer upon interaction with N-acyl hydrazone inhibitors. Molecular Pharmacology. 62: 398-405. PMID 12130693 DOI: 10.1124/mol.62.2.398  0.96
2002 Arion D, Sluis-Cremer N, Min KL, Abram ME, Fletcher RS, Parniak MA. Mutational analysis of Tyr-501 of HIV-1 reverse transcriptase. Effects on ribonuclease H activity and inhibition of this activity by N-acylhydrazones. The Journal of Biological Chemistry. 277: 1370-4. PMID 11684697 DOI: 10.1074/jbc.M110254200  0.96
2000 Sluis-Cremer N, Arion D, Parniak MA. Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs) Cellular and Molecular Life Sciences. 57: 1408-1422. PMID 11078020  0.96
2000 Parniak MA, Sluis-Cremer N. Inhibitors of HIV-1 reverse transcriptase Advances in Pharmacology (San Diego, Calif.). 49: 67-109. PMID 11013761  0.96
2000 Sluis-Cremer N, Arion D, Kaushik N, Lim H, Parniak MA. Mutational analysis of Lys65 of HIV-1 reverse transcriptase Biochemical Journal. 348: 77-82. PMID 10794716 DOI: 10.1042/0264-6021:3480077  0.96
2000 Arion D, Sluis-Cremer N, Parniak MA. Mechanism by which phosphonoformic acid resistance mutations restore 3'- azido-3'-deoxythymidine (AZT) sensitivity to AZT-resistant HIV-1 reverse transcriptase Journal of Biological Chemistry. 275: 9251-9255. PMID 10734063 DOI: 10.1074/jbc.275.13.9251  0.96
2000 Sluis-Cremer N, Dmitrienko GI, Balzarini J, Camarasa MJ, Parniak MA. Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-{spiro[4'-amino-2',2'-dioxo- 1',2'-oxathiole-5',3'- [2',5'-bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl]]}-3-ethylthymine Biochemistry. 39: 1427-1433. PMID 10684624 DOI: 10.1021/bi991682+  0.96
1998 Sluis-Cremer N, Wallace L, Burke J, Stevens J, Dirr H. Aflatoxin B1 and sulphobromophthalein binding to the dimeric human glutathione S-transferase A1-1: A fluorescence spectroscopic analysis European Journal of Biochemistry. 257: 434-442. PMID 9826190 DOI: 10.1046/j.1432-1327.1998.2570434.x  0.96
1998 Wallace LA, Sluis-Cremer N, Dirr HW. Equilibrium and kinetic unfolding properties of dimeric human glutathione transferase A1-1 Biochemistry. 37: 5320-5328. PMID 9548764 DOI: 10.1021/bi972936z  0.96
1997 Kaplan W, Hüsler P, Klump H, Erhardt J, Sluis-Cremer N, Dirr H. Conformational stability of pGEX-expressed Schistosoma japonicum glutathione S-transferase: A detoxification enzyme and fusion-protein affinity tag Protein Science. 6: 399-406. PMID 9041642  0.96
1996 Sluis-Cremer N, Naidoo N, Dirr H. Class-pi glutathione S-transferase is unable to regain its native conformation after oxidative inactivation by hydrogen peroxide European Journal of Biochemistry. 242: 301-307. PMID 8973647  0.96
1996 Sluis-Cremer N, Naidoo NN, Kaplan WH, Manoharan TH, Fahl WE, Dirr HW. Determination of a binding site for a non-substrate ligand in mammalian cytosolic glutathione S-transferases by means of fluorescence-resonance energy transfer. European Journal of Biochemistry / Febs. 241: 484-8. PMID 8917446 DOI: 10.1111/j.1432-1033.1996.00484.x  0.96
1995 Sluis-Cremer N, Dirr H. Conformational stability of Cys45-alkylated and hydrogen peroxide-oxidised glutathione S-transferase Febs Letters. 371: 94-98. PMID 7672131 DOI: 10.1016/0014-5793(95)00826-U  0.96
Show low-probability matches.